Lexaria Net Receivables vs Accounts Payable Analysis

LEXX Stock

USD 2.13 0.02 0.93%

Lexaria Bioscience financial indicator trend analysis is infinitely more than just investigating Lexaria Bioscience Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexaria Bioscience Corp is a good investment. Please check the relationship between Lexaria Bioscience Net Receivables and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexaria Bioscience Corp Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have no relationship.

The correlation between Lexaria Bioscience's Net Receivables and Accounts Payable is 0.07. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Lexaria Bioscience Corp, assuming nothing else is changed. The correlation between historical values of Lexaria Bioscience's Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Lexaria Bioscience Corp are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., Lexaria Bioscience's Net Receivables and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.07

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Accounts Payable

An accounting item on the balance sheet that represents Lexaria Bioscience obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lexaria Bioscience Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Lexaria Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

At this time, Lexaria Bioscience's Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 415.56 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.4 M in 2024.

Lexaria Bioscience fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Net Receivables	Short Term Debt	Inventory	Non Currrent Assets Other
Total Assets		-0.13	0.06	0.98	0.13	-0.87	-0.45	0.04	0.93	0.22	0.94	0.35	-0.07	0.03	0.32	0.52	0.07	0.22	0.93	-0.44	-0.12	-0.64	0.58	-0.11	-0.36	-0.17
Other Current Liab	-0.13		-0.12	-0.11	-0.31	0.11	-0.56	0.72	-0.13	-0.18	-0.12	0.55	0.07	0.63	0.57	0.56	-0.06	-0.16	-0.09	-0.11	-0.42	-0.42	0.12	-0.44	-0.38	-0.2
Total Current Liabilities	0.06	-0.12		-0.11	0.96	0.42	0.3	0.22	-0.27	0.95	-0.26	-0.51	-0.27	0.13	-0.31	-0.25	1.0	0.96	-0.28	-0.3	0.57	0.12	0.16	0.57	0.41	-0.2
Total Stockholder Equity	0.98	-0.11	-0.11		-0.04	-0.94	-0.5	0.0	0.98	0.06	0.98	0.42	-0.02	-0.01	0.38	0.56	-0.1	0.05	0.98	-0.4	-0.23	-0.67	0.54	-0.21	-0.42	-0.15
Property Plant And Equipment Net	0.13	-0.31	0.96	-0.04		0.35	0.33	0.1	-0.2	0.97	-0.2	-0.55	-0.29	0.02	-0.4	-0.29	0.95	0.97	-0.22	-0.27	0.65	0.16	0.19	0.65	0.42	-0.12
Net Debt	-0.87	0.11	0.42	-0.94	0.35		0.45	0.17	-0.99	0.28	-0.99	-0.48	-0.02	0.14	-0.34	-0.48	0.41	0.28	-0.99	0.21	0.36	0.57	-0.41	0.35	0.46	0.05
Retained Earnings	-0.45	-0.56	0.3	-0.5	0.33	0.45		-0.6	-0.44	0.14	-0.44	-0.88	-0.19	-0.6	-0.89	-0.97	0.24	0.15	-0.49	0.25	0.6	0.81	-0.48	0.62	0.63	0.37
Accounts Payable	0.04	0.72	0.22	0.0	0.1	0.17	-0.6		-0.11	0.25	-0.1	0.41	0.14	0.85	0.67	0.66	0.28	0.29	-0.08	-0.49	-0.15	-0.61	0.07	-0.19	-0.44	-0.23
Cash	0.93	-0.13	-0.27	0.98	-0.2	-0.99	-0.44	-0.11		-0.12	1.0	0.43	-0.01	-0.1	0.33	0.49	-0.26	-0.13	1.0	-0.3	-0.28	-0.6	0.46	-0.27	-0.43	-0.08
Non Current Assets Total	0.22	-0.18	0.95	0.06	0.97	0.28	0.14	0.25	-0.12		-0.12	-0.38	-0.26	0.2	-0.21	-0.08	0.95	0.99	-0.13	-0.36	0.57	-0.01	0.28	0.56	0.28	-0.17
Cash And Short Term Investments	0.94	-0.12	-0.26	0.98	-0.2	-0.99	-0.44	-0.1	1.0	-0.12		0.43	-0.01	-0.1	0.33	0.49	-0.26	-0.12	1.0	-0.31	-0.28	-0.6	0.46	-0.27	-0.43	-0.08
Common Stock Total Equity	0.35	0.55	-0.51	0.42	-0.55	-0.48	-0.88	0.41	0.43	-0.38	0.43		0.14	0.52	0.74	0.87	-0.46	-0.41	0.47	0.13	-0.76	-0.56	0.49	-0.8	-0.55	-0.41
Common Stock Shares Outstanding	-0.07	0.07	-0.27	-0.02	-0.29	-0.02	-0.19	0.14	-0.01	-0.26	-0.01	0.14		0.13	0.35	0.19	-0.26	-0.23	0.01	-0.13	-0.37	-0.2	-0.2	-0.35	0.03	-0.19
Non Current Liabilities Total	0.03	0.63	0.13	-0.01	0.02	0.14	-0.6	0.85	-0.1	0.2	-0.1	0.52	0.13		0.6	0.65	0.21	0.2	-0.08	-0.19	-0.24	-0.44	0.22	-0.28	-0.38	-0.3
Other Current Assets	0.32	0.57	-0.31	0.38	-0.4	-0.34	-0.89	0.67	0.33	-0.21	0.33	0.74	0.35	0.6		0.91	-0.26	-0.18	0.37	-0.47	-0.55	-0.87	0.15	-0.55	-0.66	-0.25
Other Stockholder Equity	0.52	0.56	-0.25	0.56	-0.29	-0.48	-0.97	0.66	0.49	-0.08	0.49	0.87	0.19	0.65	0.91		-0.19	-0.08	0.53	-0.35	-0.54	-0.86	0.47	-0.56	-0.68	-0.32
Total Liab	0.07	-0.06	1.0	-0.1	0.95	0.41	0.24	0.28	-0.26	0.95	-0.26	-0.46	-0.26	0.21	-0.26	-0.19		0.96	-0.27	-0.31	0.54	0.08	0.19	0.55	0.37	-0.22
Property Plant And Equipment Gross	0.22	-0.16	0.96	0.05	0.97	0.28	0.15	0.29	-0.13	0.99	-0.12	-0.41	-0.23	0.2	-0.18	-0.08	0.96		-0.14	-0.43	0.58	-0.05	0.22	0.58	0.24	-0.15
Total Current Assets	0.93	-0.09	-0.28	0.98	-0.22	-0.99	-0.49	-0.08	1.0	-0.13	1.0	0.47	0.01	-0.08	0.37	0.53	-0.27	-0.14		-0.3	-0.32	-0.63	0.49	-0.31	-0.44	-0.11
Common Stock	-0.44	-0.11	-0.3	-0.4	-0.27	0.21	0.25	-0.49	-0.3	-0.36	-0.31	0.13	-0.13	-0.19	-0.47	-0.35	-0.31	-0.43	-0.3		-0.3	0.73	0.12	-0.32	0.44	-0.22
Short Long Term Debt Total	-0.12	-0.42	0.57	-0.23	0.65	0.36	0.6	-0.15	-0.28	0.57	-0.28	-0.76	-0.37	-0.24	-0.55	-0.54	0.54	0.58	-0.32	-0.3		0.3	-0.19	1.0	0.06	0.66
Current Deferred Revenue	-0.64	-0.42	0.12	-0.67	0.16	0.57	0.81	-0.61	-0.6	-0.01	-0.6	-0.56	-0.2	-0.44	-0.87	-0.86	0.08	-0.05	-0.63	0.73	0.3		-0.24	0.3	0.72	0.12
Net Receivables	0.58	0.12	0.16	0.54	0.19	-0.41	-0.48	0.07	0.46	0.28	0.46	0.49	-0.2	0.22	0.15	0.47	0.19	0.22	0.49	0.12	-0.19	-0.24		-0.21	-0.1	-0.39
Short Term Debt	-0.11	-0.44	0.57	-0.21	0.65	0.35	0.62	-0.19	-0.27	0.56	-0.27	-0.8	-0.35	-0.28	-0.55	-0.56	0.55	0.58	-0.31	-0.32	1.0	0.3	-0.21		0.09	0.66
Inventory	-0.36	-0.38	0.41	-0.42	0.42	0.46	0.63	-0.44	-0.43	0.28	-0.43	-0.55	0.03	-0.38	-0.66	-0.68	0.37	0.24	-0.44	0.44	0.06	0.72	-0.1	0.09		-0.39
Non Currrent Assets Other	-0.17	-0.2	-0.2	-0.15	-0.12	0.05	0.37	-0.23	-0.08	-0.17	-0.08	-0.41	-0.19	-0.3	-0.25	-0.32	-0.22	-0.15	-0.11	-0.22	0.66	0.12	-0.39	0.66	-0.39

Click cells to compare fundamentals

Lexaria Bioscience Account Relationship Matchups

Lexaria Bioscience fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.8M	13.3M	7.8M	3.1M	3.5M	4.1M
Other Current Liab	96.7K	45K	51.7K	239.9K	275.9K	289.7K
Total Current Liabilities	225.9K	153.3K	194.0K	267.7K	241.0K	472.9K
Total Stockholder Equity	2.5M	13.3M	7.9M	3.0M	3.5M	3.4M
Property Plant And Equipment Net	610.3K	459.3K	367.9K	421.6K	379.4K	360.5K
Net Debt	(1.1M)	(10.8M)	(5.8M)	(1.2M)	(1.1M)	(1.1M)
Retained Earnings	(27.8M)	(31.8M)	(39.1M)	(45.8M)	(41.2M)	(39.1M)
Accounts Payable	45.1K	59.9K	25.8K	225.0K	258.8K	271.7K
Cash	1.3M	10.9M	5.8M	1.4M	1.6M	1.8M
Non Current Assets Total	902.3K	823.9K	856.4K	884.2K	795.8K	1.3M
Cash And Short Term Investments	1.3M	11.8M	6.2M	1.5M	1.7M	1.8M
Common Stock Shares Outstanding	2.8M	4.4M	5.9M	6.6M	7.6M	8.0M
Liabilities And Stockholders Equity	2.8M	13.3M	7.8M	3.1M	3.5M	4.1M
Non Current Liabilities Total	120.1K	50.0K	7.4K	136.2K	122.6K	216.6K
Other Current Assets	182.1K	319.3K	576.8K	546.8K	628.8K	660.2K
Other Stockholder Equity	30.3M	45.1M	47.0M	48.8M	56.1M	58.9M
Total Liab	346.0K	203.3K	201.4K	403.9K	363.5K	556.3K
Property Plant And Equipment Gross	483.4K	773.2K	747.9K	896.8K	807.1K	1.4M
Total Current Assets	1.9M	12.4M	7.0M	2.2M	2.5M	2.2M
Common Stock	90.0K	5.7K	6.0K	8.1K	9.3K	8.8K
Net Receivables	313.9K	342.4K	201.8K	175.2K	201.5K	166.0K
Inventory	116.9K	29.6K	38.4K	1.0	0.9	0.86
Non Currrent Assets Other	(902.3K)	(823.9K)	(856.4K)	(884.2K)	(795.8K)	(835.6K)
Intangible Assets	292K	364.6K	488.5K	462.6K	532.0K	558.6K
Net Tangible Assets	2.1M	2.2M	12.9M	7.5M	8.6M	5.5M
Net Invested Capital	2.6M	13.3M	7.9M	3.0M	3.5M	5.4M
Net Working Capital	1.7M	12.3M	6.8M	1.9M	2.2M	2.1M
Property Plant Equipment	591.3K	610.3K	459.3K	367.9K	423.1K	372.5K
Short Term Investments	19.3K	833.8K	347.3K	125.6K	144.5K	256.8K
Capital Stock	90.0K	5.7K	6.0K	8.1K	7.3K	6.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexaria Net Receivables vs Accounts Payable Analysis

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

Correlation Coefficient

Net Receivables

Accounts Payable

Lexaria Bioscience fundamental ratios Correlations

Lexaria Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lexaria Bioscience fundamental ratios Accounts

Also Currently Popular

Additional Tools for Lexaria Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Term Debt	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings
Net Debt	- 0.94	Total Stockholder Equity
Other Current Assets	- 0.89	Retained Earnings